Under a tenth of patients eligible to benefit from obesity jabs such as Wegovy can access them, states the World Health Organization as it publishes its initial advice on the therapies.
With over a billion individuals worldwide now obese, it is calling for more widespread and fairer availability to these injectable treatments.
Based on forecasts, more than two billion will be obese by 2030 if no action is taken.
"Our latest guidelines recognises that obesity is a lifelong illness that can be managed with thorough and continuous treatment," said WHO director-general Tedros Adhanom Ghebreyesus.
Significant expense, constrained manufacturing, and distribution challenges are significant hurdles to universal availability to the injections that can aid individuals in losing significant body mass, explains the body.
Skinny Jab Supply Crisis
Even in the present most optimistic case, the manufacturing of GLP-1 therapies would only suffice for approximately 100 million people – under 10% of the global need, according to the health organization.
The advice urges governments and firms to widen access, through approaches like voluntary licensing.
A patent on the active ingredient – the main ingredient of the drug Wegovy – is scheduled to end in multiple countries in 2026.
How Obesity Jabs Operate
These medications imitate a body's own hormone to slow digestion, reduce hunger and boost feelings of fullness so individuals eat less.
People typically see weight reduction after several weeks of commencing the once-weekly jabs.
Evidence indicates users may regain a significant portion after a year of halting the treatment, as their normal food cravings come back.
Being overweight or obese elevates your chance for experiencing health problems, such as type 2 diabetes, heart disease, stroke, and certain malignancies.
Obesity concerns people in every country and was responsible for 3.7 million fatalities worldwide in 2024, as per the health agency.
